Skip to main content

Advertisement

Table 2 Top three Ingenuity canonical pathways enriched by genes regulated after 131I or 211At exposure

From: Gene expression signature in mouse thyroid tissue after 131I and 211At exposure

Canonical pathway Nuclide Δt (h) D (Gy) p value Involved moleculesa
Calcium signalling 211At 1 0.023 0.035 DOWN: MYL1, TNNC2, TNNI2, TNNT3, TPM2
   1.4 0.001 DOWN: ACTA1, ATP2A1, ATP2A3, Calm1 (includes others), MYH1, MYH2, MYH4, MYL1, TNNC2, TNNI2, TNNT3, TPM2 UP: LETM1, PRKACA
  6 0.32 <0.0005 DOWN: ACTA1, ATP2A1, MYH1, MYL1, TNNC2, TNNI2, TNNT3, TPM2
   1.4 <0.0005 DOWN: Calm1 (includes others) UP: ACTA, ATP2A1, ATP2A3, MYH, MYH2, MYH4, RYR1, TNNC2, TNNI2, TNNT3, TPM2
  24 0.05 0.180 UP: ATP2A1, LETM1, MYH2, RYR1, TNNT3
   0.5 0.390 UP: ATP2A1, MYH2
   1.4 0.009 DOWN: ATP2A3 UP: ACTA1, ATP2A1, MYH4, TNNC2, TNNI2, TNNT3, TPM2
   11 <0.0005 DOWN: Camk2b, LETM1 UP: ACTA1, ATP2A1, ATP2A3, Calm1 (includes others), CREB3L4, MYH1, MYH2, MYH4, MYL1, RYR1, TNNC2, TNNI2, TNNT3, TP63, TPM2
   32 <0.0005 DOWN: Camk2b, LETM1 UP: ACTA1, ATP2A1, ATP2A3, CREB3L4, MYH1, MYH2, MYH4, MYL1, RYR1, TNNC2, TNNI2, TNNT3, TPM2
  168 1.8 0.027 DOWN: TNNC2, TNNI2, TNNT3 UP: MYL1
131I 24 0.85
   8.5 <0.0005 DOWN: MEF2C UP: ACTA1, ATP2A1, MYH1, MYH4, MYL1, RYR1, TNNC2, TNNI2, TNNT3, TPM2
   17 0.071 UP: ACTA1, ATP2A1
Integrin-linked kinase signalling 211At 1 0.023 0.291 DOWN: MYL1 UP: DSP, IRS2
   1.4 <0.0005 DOWN: ACTA1, ACTB, Actn3, CCND1, ITGB6, KRT18, MYH1, MYH2, MYH4, MYL1, VIM UP: IRS2, LIMS2, SH2B2, VIM, ITGB6 UP/DOWN: PPP2R5A
  6 0.32 0.004 DOWN: ACTA1, MYH1, MYL1 UP: DSP, IRS2, RHOU
   1.4 0.001 DOWN: PPAP2B UP: ACTA1, ACTN2, Actn3, DSP, MYH1, MYH2, MYH4, RHOU
  24 0.05 0.203 UP: ACTN2, LIMS2, MYH2, RHOT2 UP/DOWN: PPP2R5A
   0.5 0.413 UP: ACTN2, MYH2
   1.4 0.001 DOWN: ACTB, CCND1, CDH1, CTNNB1, ITGB4, KRT18 UP: ACTA1, FOS, IRS2, MYH4
   11 <0.0005 DOWN: Irs3, VIM UP: ACTA1, Actn3, CDH1, CREB3L4, DSP, IRS2, ITGB4, ITGB6, MYH1, MYH2, MYH4, MYL1, KRT18
   32 <0.0005 UP: ACTA1, ACTN2, Actn3, CDH1, CREB3L4, DSP, IRS2, ITGB4, ITGB6, KRT18, MYH1, MYH2, MYH4, MYL1
  168 1.8
131I 24 0.85 0.169 DOWN: ACTB, IRS2, PPAP2B UP: FOS
   8.5 0.001 DOWN: IRS2 UP: ACTA1, ACTN2, Actn3, CCND1, FOS, MYH1, MYH4, MYL1
   17 0.076 UP: ACTA1, CCND1
Thyroid cancer signalling 211At 1 0.023 0.291 DOWN: MYL1 UP: DSP, IRS2
   1.4 0.029 DOWN: CCND1, KLK3, NGF UP: PPARG
  6 0.32 0.040 DOWN: NGF DOWN/UP: KLK3
   1.4 0.019 UP: NGF, KLK3, RET
  24 0.05 0.490 DOWN/UP: KLK3
   0.5 0.036 DOWN: KLK3, UP: NGF
   1.4 0.004 DOWN: CCND1, CDH1, CTNNB1 UP: KLK3
   11 <0.0005 DOWN: NTRK2, NTRK3, PPARG UP: CDH1, KLK3, NGF, RET
   32 <0.0005 DOWN: NTRK2, NTRK3 UP: CDH1, KLK3, NGF, RET
  168 1.8 0.026 UP: KLK3, NGF
131I 24 0.85 0.370 UP: PPARG
   8.5 0.100 UP: CCND1, PPARG,
   17 0.004 UP: CCND1, KLK3
  1. DOWN and UP indicate down- and upregulation, respectively. Italics indicates no statistically significant effect on the specific canonical pathway
  2. Abbreviations: Δt exposure time, D absorbed dose
  3. aIPA predicts involved molecules in the form of human proteins